Lysosomal enzymes are enzymes or catalysts that naturally occur in
the body and help in performing different metabolic processes.
Lysosomal enzymes help break down large molecules and other
ingredients that are taken up by cells to perform different functions
of the body. The nuclear gene controls the synthesis of lysosomal
enzymes. Deficit of lysosomal enzymes due to genetic mutation causes
many complications such as storage disease, which can affect growth
and development of an organ and lead to organ faliure. During the
last two decades, there has been research and development in the
field of artificial genetic material. There have been advancements in
the treatment of lysosomal storage disorder due to development of
various therapeutic approaches such as enzyme replacement therapy,
development of synthetic enzymes, etc.
Request Brochure for Detailed Analysis @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=43670
Based on disease condition, the global synthetic lysosomal enzymes
market can be categorized into neuromuscular metabolic disorder,
thrombocytopenia disorder, storage disorder (liver enlargement,
etc.), and others. The storage disorder segment is likely to expand
at a significant pace during the forecast period, as the incidence of
storage disorders such as liver enlargement is quite high, and most
doctors prefer to use synthetic lysosomal enzymes to treat these
disorders. In terms of drug, the global synthetic lysosomal enzymes
market can be classified into imiglucerase, alglucosidase alfa,
lyronidase, idursulfase, and others. The imiglucerase segment is
expected to expand at a rapid pace during the forecast period,
because imiglucerase is a man-made enzyme and most doctors prefer to
use it in replacement therapy, which is effective in treating
enzymatic disorders. Based on distribution channel, the global
synthetic lysosomal enzymes market can be classified into hospital
pharmacies, medical stores, and online pharmacies. The hospital
pharmacies segment is likely to expand at a significant pace during
the forecast period. Patients prefer hospital pharmacies as synthetic
lysosomal enzymes drugs should be given under strict supervision.
Rise in geriatric population, which is more likely to suffer from
Duchenne muscular dystrophy, is one of the major factors fueling the
global synthetic lysosomal enzymes market. Moreover, high prevalence
of thrombocytopenia disorder is also projected to drive the market
during the forecast period. However, side effects associated with
synthetic enzymes such as breathing problems, swelling of the lips,
and itching are likely to hamper the market in the next few years.
Enquire for Discount @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=43670
In terms of region, the global synthetic lysosomal enzymes market can
be segmented into North America, Europe, Asia Pacific, Latin America,
and Middle East & Africa. North America dominates the global
market. The region is projected to account for a significant share of
the global market during the forecast period, due to rise in the
prevalence of metabolic muscular disorders. In Europe, the rise in
the geriatric population and the prevalence of Gaucher’s disease
are projected to drive the market. Rise in the prevalence of muscular
dystrophy disorder and awareness about the effects of lysosomal
storage disorders in countries such as India, the Philippines, and
Singapore are likely to fuel the market in Asia Pacific during the
forecast period. Rise in awareness about the harmful effects of
lysosomal storage disorders and high diagnosis rates are likely to
augment the synthetic lysosomal enzymes market in Middle East &
Africa during the forecast period.
Key players operating in the global synthetic lysosomal enzymes
market are Genzyme Corporation, BioMarin, Pfizer, Inc., Alexion
Pharmaceuticals, Inc., and Shire plc among others.
Request TOC of the Report for Complete Review @
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=43670
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment